Chaya Krishnamurthy, MD
Gastroenterology · Salt Lake City, UTNPI 1679767842
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 28.5% of the total.
Across 300 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$720
- Johnson & Johnson$633
- Regeneron Healthcare Solutions, Inc.$405
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$316
- Gilead$253
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,88898%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,419 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $720 |
| Johnson & Johnson | 35 | $633 |
| Regeneron Healthcare Solutions, Inc. | 22 | $405 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $316 |
| Gilead | 13 | $253 |
| Organon | 13 | $154 |
| Sanofi | 6 | $95 |
| Daiichi Sankyo Inc. | 5 | $85 |
| Madrigal Pharmaceuticals | 4 | $83 |
| QOL Medical, LLC | 6 | $78 |
| Celltrion USA Inc. | 3 | $74 |
| Boston Scientific | 5 | $70 |
| Shire North American Group Inc | 4 | $70 |
| Intercept Pharmaceuticals, Inc. | 4 | $57 |
| Bristol Myers Squibb | 4 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $50 |
| Amgen | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Pfizer | 2 | $33 |
| Orphalan Inc | 1 | $32 |
| Capsovision, Inc. | 1 | $26 |
| AstraZeneca | 2 | $24 |
| Merck | 2 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Ardelyx, Inc. | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$122
How this compares
$4,988 in reported general payments places this provider in the 70th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 11 | $2,767 |
| Omeprazole | 42 | $1,039 |
| Rabeprazole Sodium | 20 | $814 |
| Tenofovir Disoproxil Fumarate | 12 | $633 |
| Spironolactone | 24 | $231 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Salt Lake City
- Terry BoxSalt Lake City$302K
- Richard GilroySalt Lake City$192K
- Kathryn PetersonSalt Lake City$111K
- John FangSalt Lake City$12K
- Iqbal SandhuSalt Lake City$10K
- John ValentineSalt Lake City$9K
- Ann FlynnSalt Lake City$6K
- Suryanarayana ChallaSalt Lake City$6K
- Jason WillsSalt Lake City$6K
- Ramon Minjares GranilloSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.